Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
 
COORDINADOR

Coordinador: Dr. Luis Montuenga Badia
Centro: Centro para la Investigación Médica Aplicada
Dirección postal: Avda. Pío XII, 55, 31008, Pamplona
Email: lmontuenga[arroba]unav.es

Breve CV: Dr. Luis M. Montuenga got his undergraduate degree with Honors in Biology from the University of Navarra (Spain). He also has a Master of Sciences (MSc) in Neuroendocrine Cell Biology from University College London (UK). In 1984 got his Ph.D. in Biology from the University of Navarra (Spain). He spent two years as postgraduate fellow at the Royal Postgraduate Medical School in London and was Visiting Scientist at the National Cancer Institute (NIH) in Bethesda (Maryland) during three years (1995-1998). He is currently Full Professor of Cell Biology at the School of Medicine of the University of Navarra and Senior Researcher and Head of the Oncology Division of the Center for Applied Medical Research (CIMA), University of Navarra. In the past Dr. Montuenga has been the Head of the Histology and Pathology Department of the School of Medicine (1998-2007) and Vicepresident of Research of the University of Navarra (2008-2011). 

Dr. Montuenga has authored more than 120 peer-reviewed publications in Cell Biology and Oncology, has directed 18 doctoral theses and has given numerous conferences and seminars internationally. His research activity is primarily focused on lung cancer. At the Center of Applied Medical Research he co-leads, together with Dr. Ruben Pio, the Laboratory of Lung Cancer Biomarkers. The laboratory of Biomarker’s is focused on the molecular mechanisms associated with the transformation of normal lung epithelial cells into lung tumors. One of its main translational aims is to find molecular markers related to lung carcinogenesis to develop new strategies for lung cancer early detection. Other research interest of the group is to design new molecular targeted therapies that may be useful in the treatment of lung tumors.

He has served as ad hoc reviewer in a variety of national and international research evaluation agencies and has been involved in the peer review process of a large number of journals of his research field.  He is currently Associate Editor of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

He is founding member of the European Union Early Lung Cancer (EUELC), member of the prevention Committee of the IASLC, Active member of the American Association for Cancer Research (AACR) and the European Respiratory Society as well as Spanish scientific research societies like the Asociación Española de Investigación en Cáncer (ASEICA) or the Spanish Society for Cell Biology (SEBC).

In the past editions of the RTICC network, Dr. Montuenga has been the Coordinator for Training and Mobility and now serves as Coordinator of the Respiratory Tract Tumors Program.

Introducción
Coordinador
Grupos
Work Packages
Publicaciones
Proyectos
Ensayos clínicos
Otros resultados
Agenda
Enlaces
Intranet
Noticias
Publicaciones
RD12/0036/0028
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, Galimi F, Haddad V, Sabin T, Hei YJ, Pan Y, Cottrell S, Hsu CP, RamLau R
J Thorac Oncol  2013.  3.  329-37.  PMID: 23370314. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage.
Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Romero-Romero B, Mediano MD, López-Campos JL, García-Carbonero R, Sanchez-Gastaldo A, Carnero A, Paz-Ares L
Int J Mol Sci  2013.  2.  3440-55.  PMID: 23389041. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer.
Gridelli C, Paz-Ares L
Eur J Cancer  2013.  9.  2271-2.  PMID: 23541565. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Proteomic biomarkers in lung cancer.
Pastor MD, Nogal A, Molina-Pinelo S, Carnero A, Paz-Ares L
Clin Transl Oncol  2013.  9.  671-82.  PMID: 23606351. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Identification of proteomic signatures associated with lung cancer and COPD.
Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Salinas A, González De la Peña M, Martín-Juan J, Corral J, García-Carbonero R, Carnero A, Paz-Ares L
J Proteomics  2013.  227-37.  PMID: 23665002. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Lung cancer in 2013: state of the art therapy for metastatic disease.
Shepherd FA, Bunn PA, Paz-Ares L
Am Soc Clin Oncol Educ Book  2013.  339-46.  PMID: 23714542. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.
Estevez-Garcia P, Lopez-Calderero I, Molina-Pinelo S, Muñoz-Galvan S, Salinas A, Gomez-Izquierdo L, Lucena-Cacace A, Felipe-Abrio B, Paz-Ares L, Garcia-Carbonero R, Carnero A
Clin Cancer Res  2013.  14.  3925-35.  PMID: 23729363. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Inhibition of HSP90 molecular chaperones: moving into the clinic.
Garcia-Carbonero R, Carnero A, Paz-Ares L
Lancet Oncol  2013.  9.  e358-69.  PMID: 23896275. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
Molina-Pinelo S, Pastor MD, Paz-Ares L
Expert Rev Respir Med  2014.  1.  1-4.  PMID: 24308656. 
Grupos colaboradores: RD12/0036/0028

RD12/0036/0028
Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.
Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz-Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA
J Cancer Res Clin Oncol  2015.  1.  43-53.  PMID: 25081930. 
Grupos colaboradores: RD12/0036/0028

ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
 
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
 
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS